A systematic review to assess adherence and persistence with statins

被引:68
作者
Deshpande, Sohan [1 ]
Quek, Ruben G. W. [2 ]
Forbes, Carol A. [1 ]
de Kock, Shelley [1 ]
Kleijnen, Jos [1 ,3 ]
Gandra, Shravanthi R. [2 ]
Simpson, Ross J., Jr. [4 ,5 ]
机构
[1] Kleijnen Systemat Reviews Ltd, Unit 6,Escrick Business Pk,Riccall Rd, York YO19 6FD, N Yorkshire, England
[2] Amgen Inc, One Amgen Ctr Dr, Thousand Oaks, CA USA
[3] Maastricht Univ, Sch Publ Hlth & Primary Care, Maastricht, Netherlands
[4] UNC Hosp Heart & Vasc Ctr Meadowmont, Chapel Hill, NC USA
[5] Vasc Ctr Meadowmont, Chapel Hill, NC USA
关键词
Adherence; Cardiovascular diseases; Hypercholesterolemia; Persistence; Review; systematic; Statins; CORONARY-HEART-DISEASE; LIPID-LOWERING THERAPY; MEDICATION ADHERENCE; CARDIOVASCULAR-DISEASE; TREATMENT PATTERNS; DRUG-THERAPY; RISK-FACTORS; CARE; NONADHERENCE; ASSOCIATION;
D O I
10.1080/03007995.2017.1281109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To identify and assess studies published over a 10 year period up to February 2016 which measure adherence or persistence with statins, to summarize their methods, strengths and weaknesses and to summarize evidence linking statin adherence/persistence with risk of cardiovascular events. Methods: Electronic databases and abstracts from four major cardiovascular disease conferences were searched from January 2005 to February 2016. The study selection process was performed by two reviewers working independently. Studies were included if they reported data regarding patient adherence or persistence with statins in adults with primary hypercholesterolemia, using any type of study design or length of follow-up. One reviewer extracted the study data and assessed study quality, which was checked by a second reviewer independently. Given the heterogeneity between the included studies a narrative critique and summary is presented. Results: We report on 84 real world studies which aimed to assess adherence or persistence with statins. The majority of studies concluded that good adherence/persistence was associated with reduction in cardiovascular events and mortality. In two studies high intensity statin regimens were associated with poorer patient adherence when compared to low intensity statins. Adherence and persistence with statin therapy also has an impact on hospitalization costs and other cardiovascular disease (CVD) related costs. Conclusions: Adherence and persistence are associated with a reduction in CVD events and mortality. There was limited evidence to suggest that high intensity statin regimens are associated with poorer treatment adherence when compared to lower intensity regimens. Hence, more robust studies are required to establish this association. As recommended by the 2013 ACC/AHA, 2016 ESC and several other clinical guidelines, clinicians and pharmacy managers should regularly monitor statin therapy adherence.
引用
收藏
页码:769 / 778
页数:10
相关论文
共 88 条
[21]  
Cunico Cassia, 2014, Pharm Pract (Granada), V12, P378
[22]   Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review [J].
De Vera, Mary A. ;
Bhole, Vidula ;
Burns, Lindsay C. ;
Lacaille, Diane .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) :684-698
[23]   Adherence to Statin Treatment and Health Outcomes in an Italian Cohort of Newly Treated Patients: Results From an Administrative Database Analysis [J].
Degli Esposti, Luca ;
Saragoni, Stefania ;
Batacchi, Paolo ;
Benemei, Silvia ;
Geppetti, Pierangelo ;
Sturani, Alessandra ;
Buda, Stefano ;
Degli Esposti, Ezio .
CLINICAL THERAPEUTICS, 2012, 34 (01) :190-199
[24]  
Dissemination C.for R., 2009, CRD's guidance for undertaking reviews in health care
[25]   Long-term adherence to statin treatment in diabetes [J].
Donnelly, L. A. ;
Doney, A. S. F. ;
Morris, A. D. ;
Palmer, C. N. A. ;
Donnan, P. T. .
DIABETIC MEDICINE, 2008, 25 (07) :850-855
[26]   The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions [J].
Downs, SH ;
Black, N .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1998, 52 (06) :377-384
[27]  
Eren NK, 2014, MINERVA CARDIOANGIOL, V62, P287
[28]  
European Medicines Agency, 2010, EMACPMP30202003
[29]  
FERRAJOLO C, 2014, PLOS ONE, V9
[30]  
Gibson TB, 2006, AM J MANAG CARE, V12, pSP11